Deciphering prognostic markers in gastric signet ring cell carcinoma: Human epidermal growth factor receptor 2 and other key factors

Table 1 Clinicopathologic variables in relation to survival

Clinicopathological variable		Number	Recurrence	P value	Death	P value
Age	≤ 50	51	27	0.62000	41	0.11000
	> 50	49	25		30
Sex	Male	49	24	0.17000	30	0.01070a
	Female	51	28		41
CA 19-9 serum level	> 100 ng/mL	36	16	0.79000	35	0.00149a
	≤ 100 ng/mL	64	36		36
CEA serum level	> 10 U/mL	35	15	0.50000	35	0.00163a
	≤ 10 U/mL	65	37		36
TNM stage	I	33	21	0.77000	5	< 0.00100a
	II	32	16		31
	III	19	10		19
	IV	16	5		16
Stage	Advanced	35	15	0.50000	35	0.00169a
	Localized	65	37		36
T stage	Mucosa	22	11	0.50000	15	0.23000
	Submucosa	19	8		13
	Muscularis propria	31	15		24
	Serosa	28	18		19
Tumor size	< 5.75 cm	49	23	0.89000	37	0.24000
	≥ 5.75 cm	51	29		34
Lymph node status	Positive	71	34	0.80000
	Negative	29	18
Tumor location	Diffuse	46	24	0.62000	33	0.52000
	Antrum	35	16		27
	Body	12	7		6
	Fundus	3	2		2
	Cardia	4	3		3
Tumor morphology	Infiltrative	52	26	0.94000	44	0.06800
	Ulcerative	41	23		24
	Polypoid	7	3		3
Surgical margin	Positive	12	41	0.00956a	8	0.64000
	Negative	88	11		63
Lymphovascular invasion	Present	80	41	0.51000	61	0.01900a
	Absent	20	11		10
Perineural invasion	Present	59	33	0.62000	41	0.68000
	Absent	41	19		30
HER2	Positive	15	7	0.53000	15	0.00882a
	Negative	85	45		56
Treatment	Non-surgical	38	19	0.62000	31	0.02260a
	Surgical	27	14		16
	Combined	35	19		24
Distant metastases	Present	58	28	0.22000	41	0.46000
	Absent	42	24		30

^aP < 0.05, the results have statistical significance. CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis; HER2: Human epidermal growth factor receptor 2.